Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund grew its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,475,212 shares of the biopharmaceutical company’s stock after purchasing an additional 1,039 shares during the period. New York State Common Retirement Fund owned 0.50% of Amicus Therapeutics worth $20,933,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of FOLD. China Universal Asset Management Co. Ltd. boosted its stake in shares of Amicus Therapeutics by 97.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,368 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 3,638 shares during the last quarter. Park Avenue Securities LLC purchased a new position in shares of Amicus Therapeutics during the 3rd quarter worth about $128,000. Campbell & CO Investment Adviser LLC purchased a new position in shares of Amicus Therapeutics during the 3rd quarter worth about $134,000. Los Angeles Capital Management LLC purchased a new position in shares of Amicus Therapeutics during the 3rd quarter worth about $158,000. Finally, O Shaughnessy Asset Management LLC lifted its holdings in shares of Amicus Therapeutics by 25.3% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company’s stock worth $185,000 after acquiring an additional 3,082 shares during the period.

Insider Activity at Amicus Therapeutics

In other news, Director Margaret G. Mcglynn sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $13.40, for a total transaction of $100,500.00. Following the sale, the director now owns 59,289 shares in the company, valued at $794,472.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Chairman John F. Crowley sold 31,614 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $13.81, for a total transaction of $436,589.34. Following the sale, the chairman now owns 697,628 shares in the company, valued at $9,634,242.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Margaret G. Mcglynn sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $13.40, for a total transaction of $100,500.00. Following the sale, the director now owns 59,289 shares in the company, valued at approximately $794,472.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,108 shares of company stock worth $662,605. Company insiders own 2.10% of the company’s stock.

Amicus Therapeutics Trading Up 1.1 %

NASDAQ FOLD opened at $10.28 on Friday. Amicus Therapeutics, Inc. has a one year low of $9.70 and a one year high of $14.57. The company’s 50 day moving average price is $11.88 and its 200 day moving average price is $11.99. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.52 and a current ratio of 2.88. The firm has a market capitalization of $3.04 billion, a price-to-earnings ratio of -20.16 and a beta of 0.75.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. The business had revenue of $115.08 million during the quarter, compared to analysts’ expectations of $115.11 million. On average, sell-side analysts predict that Amicus Therapeutics, Inc. will post 0.01 EPS for the current year.

Wall Street Analysts Forecast Growth

FOLD has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a report on Thursday, February 29th. JPMorgan Chase & Co. cut their price objective on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, March 18th.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.